Logo image of EAR

EARGO INC (EAR) Stock Fundamental Analysis

NASDAQ:EAR - Nasdaq - US2700872086 - Common Stock - Currency: USD

2.57  -0.11 (-4.1%)

After market: 2.6 +0.03 (+1.17%)

Fundamental Rating

3

Overall EAR gets a fundamental rating of 3 out of 10. We evaluated EAR against 189 industry peers in the Health Care Equipment & Supplies industry. EAR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. EAR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year EAR has reported negative net income.
In the past year EAR has reported a negative cash flow from operations.
In the past 5 years EAR always reported negative net income.
EAR had a negative operating cash flow in each of the past 5 years.
EAR Yearly Net Income VS EBIT VS OCF VS FCFEAR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 -50M -100M -150M

1.2 Ratios

EAR's Return On Assets of -154.97% is on the low side compared to the rest of the industry. EAR is outperformed by 89.90% of its industry peers.
With a Return On Equity value of -239.84%, EAR is not doing good in the industry: 82.83% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -154.97%
ROE -239.84%
ROIC N/A
ROA(3y)-76.89%
ROA(5y)-90.17%
ROE(3y)-133.18%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EAR Yearly ROA, ROE, ROICEAR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 0 1K 2K 3K 4K

1.3 Margins

EAR has a worse Gross Margin (41.94%) than 63.13% of its industry peers.
EAR's Gross Margin has improved in the last couple of years.
EAR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 41.94%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.62%
GM growth 5Y3.34%
EAR Yearly Profit, Operating, Gross MarginsEAR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 0 -100 -200 -300 -400

More info and screens

6

2. Health

2.1 Basic Checks

EAR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EAR has more shares outstanding
There is no outstanding debt for EAR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
EAR Yearly Shares OutstandingEAR Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M
EAR Yearly Total Debt VS Total AssetsEAR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -13.28, we must say that EAR is in the distress zone and has some risk of bankruptcy.
EAR has a worse Altman-Z score (-13.28) than 82.83% of its industry peers.
EAR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -13.28
ROIC/WACCN/A
WACC9.84%
EAR Yearly LT Debt VS Equity VS FCFEAR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 0 100M -100M

2.3 Liquidity

EAR has a Current Ratio of 3.22. This indicates that EAR is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.22, EAR perfoms like the industry average, outperforming 46.97% of the companies in the same industry.
A Quick Ratio of 2.97 indicates that EAR has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.97, EAR is in line with its industry, outperforming 57.58% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.22
Quick Ratio 2.97
EAR Yearly Current Assets VS Current LiabilitesEAR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 90.73% over the past year.
The Revenue has grown by 19.51% in the past year. This is quite good.
EAR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 41.27% yearly.
EPS 1Y (TTM)90.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.77%
Revenue 1Y (TTM)19.51%
Revenue growth 3Y4.34%
Revenue growth 5Y41.27%
Sales Q2Q%4.55%

3.2 Future

Based on estimates for the next years, EAR will show a small growth in Earnings Per Share. The EPS will grow by 1.04% on average per year.
EAR is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.88% yearly.
EPS Next Y93.38%
EPS Next 2Y1.04%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year19.87%
Revenue Next 2Y6.88%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
EAR Yearly Revenue VS EstimatesEAR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
EAR Yearly EPS VS EstimatesEAR Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EAR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EAR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EAR Price Earnings VS Forward Price EarningsEAR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EAR Per share dataEAR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.04%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

EAR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EARGO INC

NASDAQ:EAR (2/15/2024, 8:00:01 PM)

After market: 2.6 +0.03 (+1.17%)

2.57

-0.11 (-4.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-22 2024-02-22/amc
Earnings (Next)05-09 2024-05-09/amc
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners40.87%
Ins Owner Change0%
Market Cap53.38M
Analysts45
Price Target2.04 (-20.62%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-3.17%
Min Revenue beat(2)-3.73%
Max Revenue beat(2)-2.61%
Revenue beat(4)2
Avg Revenue beat(4)26.56%
Min Revenue beat(4)-3.73%
Max Revenue beat(4)58.7%
Revenue beat(8)3
Avg Revenue beat(8)-8.72%
Revenue beat(12)6
Avg Revenue beat(12)-7.44%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.3
P/FCF N/A
P/OCF N/A
P/B 1.18
P/tB 1.2
EV/EBITDA N/A
EPS(TTM)-57.98
EYN/A
EPS(NY)-56.76
Fwd EYN/A
FCF(TTM)-3.66
FCFYN/A
OCF(TTM)-3.63
OCFYN/A
SpS1.98
BVpS2.18
TBVpS2.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -154.97%
ROE -239.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 41.94%
FCFM N/A
ROA(3y)-76.89%
ROA(5y)-90.17%
ROE(3y)-133.18%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.62%
GM growth 5Y3.34%
F-Score5
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11.18%
Cap/Sales 1.34%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.22
Quick Ratio 2.97
Altman-Z -13.28
F-Score5
WACC9.84%
ROIC/WACCN/A
Cap/Depr(3y)123.26%
Cap/Depr(5y)197.27%
Cap/Sales(3y)7.58%
Cap/Sales(5y)9.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.77%
EPS Next Y93.38%
EPS Next 2Y1.04%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)19.51%
Revenue growth 3Y4.34%
Revenue growth 5Y41.27%
Sales Q2Q%4.55%
Revenue Next Year19.87%
Revenue Next 2Y6.88%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y32.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.24%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-16.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-26.69%
OCF growth 3YN/A
OCF growth 5YN/A